Cost-effectiveness analysis of the Oncotype DX Breast Recurrence Score test in node-positive early breast cancer.
- DOI
- 10.1080/13696998.2022.2066399
- Published
- 2022 Jan-Dec
- Container
- Journal of medical economics
- Publisher
- Not recorded
- Open access
- unknown
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1080/13696998.2022.2066399,
title = {Cost-effectiveness analysis of the Oncotype DX Breast Recurrence Score test in node-positive early breast cancer.},
author = {Berdunov V and Millen S and Paramore A and Hall P and Perren T and Brown R and Griffin J and Reynia S and Fryer N and Longworth L},
year = {2022},
journal = {Journal of medical economics},
doi = {10.1080/13696998.2022.2066399},
url = {https://doi.org/10.1080/13696998.2022.2066399}
}RIS
TY - JOUR TI - Cost-effectiveness analysis of the Oncotype DX Breast Recurrence Score test in node-positive early breast cancer. AU - Berdunov V AU - Millen S AU - Paramore A AU - Hall P AU - Perren T AU - Brown R AU - Griffin J AU - Reynia S AU - Fryer N AU - Longworth L PY - 2022 JO - Journal of medical economics DO - 10.1080/13696998.2022.2066399 UR - https://doi.org/10.1080/13696998.2022.2066399 ER -
APA
V, B., S, M., A, P., P, H., T, P., R, B., J, G., S, R., N, F., & L, L. (2022). Cost-effectiveness analysis of the Oncotype DX Breast Recurrence Score test in node-positive early breast cancer.. Journal of medical economics. https://doi.org/10.1080/13696998.2022.2066399
Source records
- pubmed · retrieved 2026-09-26T03:59:14.434Z